X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3322) 3322
Book Review (428) 428
Publication (233) 233
Book Chapter (12) 12
Conference Proceeding (12) 12
Dissertation (3) 3
Book / eBook (2) 2
Paper (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3057) 3057
humans (2593) 2593
camptothecin - analogs & derivatives (2494) 2494
oncology (1577) 1577
female (1447) 1447
camptothecin - administration & dosage (1418) 1418
male (1357) 1357
irinotecan (1178) 1178
camptothecin - pharmacokinetics (1170) 1170
animals (1121) 1121
pharmacology & pharmacy (1096) 1096
camptothecin (1007) 1007
middle aged (983) 983
cancer (940) 940
aged (921) 921
adult (846) 846
chemotherapy (761) 761
pharmacokinetics (710) 710
antineoplastic combined chemotherapy protocols - therapeutic use (681) 681
camptothecin - therapeutic use (664) 664
camptothecin - adverse effects (662) 662
mice (661) 661
camptothecin - pharmacology (651) 651
cpt-11 (578) 578
antineoplastic agents, phytogenic - pharmacokinetics (571) 571
colorectal neoplasms - drug therapy (551) 551
neoplasms - drug therapy (484) 484
treatment outcome (483) 483
antineoplastic agents, phytogenic - administration & dosage (450) 450
cell line, tumor (440) 440
colorectal cancer (413) 413
dose-response relationship, drug (402) 402
camptothecin - chemistry (393) 393
sn-38 (355) 355
antineoplastic combined chemotherapy protocols - adverse effects (350) 350
phase-i (338) 338
antineoplastic agents - pharmacokinetics (335) 335
drug administration schedule (334) 334
fluorouracil - administration & dosage (315) 315
antineoplastic agents - administration & dosage (314) 314
topotecan (312) 312
colorectal neoplasms - pathology (311) 311
antineoplastic agents, phytogenic - therapeutic use (309) 309
medicine & public health (307) 307
tumors (307) 307
antitumor-activity (304) 304
antineoplastic agents - pharmacology (302) 302
rats (296) 296
care and treatment (295) 295
fluorouracil (285) 285
drugs (283) 283
analysis (282) 282
antineoplastic agents - therapeutic use (282) 282
pharmacology/toxicology (280) 280
toxicity (280) 280
antineoplastic agents (278) 278
antineoplastic combined chemotherapy protocols - administration & dosage (274) 274
topoisomerase i inhibitors (273) 273
drug delivery systems (269) 269
antimitotic agents (262) 262
cell lung-cancer (261) 261
nanoparticles (259) 259
camptothecin - blood (258) 258
antineoplastic agents, phytogenic - adverse effects (254) 254
metastatic colorectal-cancer (251) 251
research (251) 251
antineoplastic agents, phytogenic - pharmacology (250) 250
drug therapy (236) 236
mice, nude (236) 236
area under curve (230) 230
infusions, intravenous (230) 230
topoisomerase-i (219) 219
glucuronosyltransferase - genetics (214) 214
lung neoplasms - drug therapy (213) 213
oxaliplatin (212) 212
trial (207) 207
leucovorin - administration & dosage (204) 204
xenograft model antitumor assays (203) 203
chemistry, multidisciplinary (202) 202
therapy (202) 202
cancer research (198) 198
leucovorin (198) 198
phase-ii (198) 198
solid tumors (198) 198
5-fluorouracil (197) 197
camptothecin - metabolism (197) 197
metastasis (197) 197
organoplatinum compounds - administration & dosage (195) 195
neoplasm metastasis (191) 191
maximum tolerated dose (190) 190
aged, 80 and over (188) 188
tissue distribution (184) 184
article (180) 180
dna topoisomerase-i (180) 180
antineoplastic agents - adverse effects (176) 176
combination (173) 173
diarrhea - chemically induced (172) 172
active metabolite (168) 168
cell survival - drug effects (168) 168
cisplatin (168) 168
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3252) 3252
Japanese (39) 39
Chinese (24) 24
French (14) 14
German (4) 4
Italian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3843 - 3854
Sacituzumab govitecan (IMMU‐132), an antibody‐drug conjugate targeting SN‐38 to Trop‐2 (an antigen identified in many epithelial cancers), is exhibiting... 
clinical trial | trophoblastic cell‐surface antigen (Trop‐2) | epithelial cancers | antibody‐drug conjugate | IMMU‐132 (sacituzumab govitecan) | SN‐38 | trophoblastic cell-surface antigen (Trop-2) | SN-38 | antibody-drug conjugate | IMMU-132 (sacituzumab govitecan) | METABOLITES | SOLID TUMORS | ETIRINOTECAN PEGOL NKTR-102 | CLINICAL PHARMACOKINETICS | BREAST-CANCER | EZN-2208 | ONCOLOGY | COLORECTAL-CANCER | THERAPEUTIC TARGET | IRINOTECAN | trophoblastic cellsurface antigen (Trop-2) | Neoplasms - metabolism | Humans | Middle Aged | Half-Life | Immunoconjugates - pharmacokinetics | Male | Response Evaluation Criteria in Solid Tumors | Immunoconjugates - administration & dosage | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Camptothecin - blood | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Irinotecan | Aged | Immunoglobulin G - metabolism | Usage | Care and treatment | Safety and security measures | Analysis | Epithelial tumors | Pharmacokinetics | Antibody-drug conjugates | Camptothecin | Antigens | Toxicity | Immunoglobulin G | Radioactive half-life | Breast cancer | Pharmacology | Metastasis | Criteria | Patients | Cell surface | Metastases | Uridine | Safety | Solid tumors | Drug dosages | Cancer | Tumors | Half life | Neutropenia | Glucuronosyltransferase | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2604 - 2614
Purpose We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11)... 
CELL LUNG-CANCER | GENETIC POLYMORPHISMS | MESSENGER-RNA | ONCOLOGY | SLCO1B1 POLYMORPHISM | RESISTANCE | HUMAN LIVER | EXPRESSION | METASTATIC COLORECTAL-CANCER | FUNCTIONAL-SIGNIFICANCE | JAPANESE SUBJECTS | Multivariate Analysis | Glucuronides - pharmacokinetics | Hepatocyte Nuclear Factor 1-alpha - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Biotransformation - genetics | Male | Organic Anion Transporters - metabolism | Patient Selection | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Organic Anion Transporters - genetics | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Multidrug Resistance-Associated Proteins - genetics | Neutropenia - chemically induced | Neutropenia - genetics | Antineoplastic Agents, Phytogenic - pharmacokinetics | Colorectal Neoplasms - metabolism | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Genetic Predisposition to Disease | Drug Administration Schedule | Risk Assessment | Risk Factors | Treatment Outcome | Polymorphism, Genetic | Bilirubin - blood | Phenotype | Glucuronosyltransferase - metabolism | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Multidrug Resistance-Associated Proteins - metabolism | Index Medicus | Original Reports | Gic7 | Faze
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2003, Volume 9, Issue 9, pp. 3246 - 3253
Purpose: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding... 
GILBERTS-SYNDROME | 7-ETHYL-10-HYDROXYCAMPTOTHECIN SN-38 | CANCER-PATIENTS | UDP-GLUCURONOSYLTRANSFERASE GENE | CPT-11 | METABOLISM | ONCOLOGY | IN-VIVO | RESISTANCE | PHARMACOGENETICS | CLINICAL PHARMACOKINETICS | Cytochrome P-450 CYP3A | Humans | Middle Aged | Adenosine Triphosphate - genetics | Male | Glucuronosyltransferase - genetics | ATP-Binding Cassette Transporters - genetics | Membrane Transport Proteins - genetics | Adult | Female | Multidrug Resistance-Associated Proteins - genetics | Glucuronates - chemistry | Neoplasm Proteins - genetics | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Gene Frequency | Genotype | DNA-Binding Proteins - genetics | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | Polymorphism, Genetic | Homozygote | Irinotecan | Phenotype | Models, Biological | Alleles | Carboxylesterase - genetics | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Protein Binding | Aged | X-ray Repair Cross Complementing Protein 1 | Camptothecin - pharmacology | Index Medicus | P-Glycoprotein/genetics | Research Support; U.S. Gov't; P.H.S | Multidrug Resistance-Associated Proteins/genetics | Cytochrome P-450 Enzyme System/genetics | Medical and Health Sciences | Medicin och hälsovetenskap | Carboxylesterase/genetics | MEDICINE | Glucuronic Acids/chemistry | Neoplasm Proteins/genetics | Polymorphism; Genetic | Models; Biological | Membrane Transport Proteins/genetics | DNA-Binding Proteins/genetics | MEDICIN | Cell Line; Tumor | Adenosine Triphosphate/genetics | ATP-Binding Cassette Transporters/genetics | Camptothecin/analogs & derivatives/pharmacokinetics/pharmacology | Glucuronosyltransferase/genetics
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF NANOMEDICINE, ISSN 1178-2013, 2019, Volume 14, pp. 3799 - 3817
Background and aim: We have synthesized a novel lactone-stabilized camptothecin (CPT) analog named CZ48 and demonstrated its potent anticancer effects via... 
nanosuspension | CZ48 | STABILIZATION | NANOSCIENCE & NANOTECHNOLOGY | TOXICITY | FORMULATION | anticancer | NANOPARTICLES | camptothecin | ESTERS | sustained drug delivery | 9-NITROCAMPTOTHECIN | PHARMACOLOGY & PHARMACY | DRUG NANOCRYSTALS | CPT | pharmacokinetics | efficacy
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue 6, pp. 1560 - 1567
Journal Article
Journal Article
Advanced Materials, ISSN 0935-9648, 06/2014, Volume 26, Issue 21, pp. 3433 - 3440
MoS 2 nanosheets functionalized with poly­ethylene glycol are for the first time used as a multifunctional drug delivery system with high drug loading... 
MoS | combination therapy | drug delivery | 2D nanostructure | nanosheet | photothermal therapy | GRAPHENE OXIDE | CELLS | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | METAL DICHALCOGENIDE NANOSHEETS | NANOSCIENCE & NANOTECHNOLOGY | TUMOR VASCULATURE | CHEMISTRY, MULTIDISCIPLINARY | NANOPARTICLES | THERAPY | NANOGRAPHENE | CHEMISTRY | NANOTUBES | Molybdenum - chemistry | Drug Carriers - adverse effects | Porphyrins - administration & dosage | Humans | Polyethylene Glycols - adverse effects | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Porphyrins - pharmacokinetics | Radiation-Sensitizing Agents - pharmacokinetics | Drug Carriers - chemistry | Phototherapy - methods | Molybdenum - adverse effects | Radiation-Sensitizing Agents - administration & dosage | Disulfides - chemistry | Camptothecin - administration & dosage | Female | Nanostructures - adverse effects | Antineoplastic Agents - pharmacokinetics | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Cell Survival - drug effects | KB Cells | Disulfides - adverse effects | Combined Modality Therapy | Disulfides - chemical synthesis | Doxorubicin - pharmacokinetics | Mammary Neoplasms, Experimental - therapy | Pilot Projects | Animals | Cell Line, Tumor | Nanostructures - chemistry | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | HeLa Cells | Drugs | Chemotherapy | Drug delivery systems | Vehicles | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2014, Volume 74, Issue 6, pp. 1125 - 1137
The aim of the study was to demonstrate the activity of etirinotecan pegol, a polymer conjugate of irinotecan, in multiple human tumor models and to establish... 
Medicine & Public Health | SN38 | Anticancer activity | Etirinotecan pegol | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Topoisomerase 1 inhibition | XENOGRAFT MODELS | IRINOTECAN CPT-11 | SOLID TUMORS | MULTICENTER PHASE-II | ANTICANCER AGENTS | OVARIAN-CANCER | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | BREAST-CANCER | 2 SCHEDULES | ONCOLOGY | PHARMACOLOGY & PHARMACY | Species Specificity | Humans | Male | Antineoplastic Agents - administration & dosage | Heterocyclic Compounds, 4 or More Rings - pharmacology | Neoplasms, Experimental - pathology | Topoisomerase I Inhibitors - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Camptothecin - analogs & derivatives | Polyethylene Glycols - pharmacology | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Topoisomerase I Inhibitors - pharmacokinetics | Topoisomerase I Inhibitors - administration & dosage | Polyethylene Glycols - pharmacokinetics | Rats | Treatment Outcome | Mice, SCID | Rats, Sprague-Dawley | Polyethylene Glycols - administration & dosage | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 4 or More Rings - pharmacokinetics | Mice, Nude | Dogs | Mice | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Plasma physics | Polymers | Analysis | Lung cancer | Cancer | Index Medicus | Original
Journal Article
Journal Article